DETROIT – Robert A. Chapman, M.D., director of the Henry Ford Cancer Institute at Henry Ford Health System, has been appointed to a three-year term on the Michigan Cancer Consortium Board of Directors.
His appointment begins January 2015.
The Michigan Cancer Consortium is a state-wide organization supported by the Michigan Department of Community Health. Its focus is to reduce the human and economic burden of cancer. Membership consists of more than 120 health care organizations across the state.
In his position on the Board of Directors, Dr. Chapman will represent Henry Ford Health System and the Henry Ford Cancer Institute, as he works with colleagues to achieve the Consortium's cancer prevention and control priorities.
Dr. Chapman, an expert in lung cancer, is passionate about improving access to early detection, screening and treatment for cancer patients in Michigan.
He previously secured a competitive Medicare grant to study disparities in cancer care in the African American population. Henry Ford was awarded $5.2 million in national funding to determine if working to overcome barriers such as transportation, assistance with co-pays and facilitating cancer screenings, diagnosis and treatment, could reduce disparities in cancer death rates among African Americans.
Since the project began in 2006, nearly 6,000 African American participants have been recruited for the project and results have been significant, including more than doubling the rates for breast, colorectal, and prostate cancer screenings.
Dr. Chapman heads the Division of Hematology/Oncology at Henry Ford Hospital. He formerly chaired a National Cancer Institute Scientific Review Committee responsible for making research funding recommendations, and served on the American Cancer Society and the governing board of the Southwest Oncology Group.
Additionally, he was recently appointed to the Board of Directors for the Safety Net Hospitals for Pharmaceutical Access.
Dr. Chapman received his medical degree from Cornell University Medical School, and completed his internal medicine residency at Henry Ford Health System and his medical oncology training at the Memorial Sloan Kettering Cancer Center.